ATE305041T1 - Kompositionen und verwendungen von cgi-69 - Google Patents
Kompositionen und verwendungen von cgi-69Info
- Publication number
- ATE305041T1 ATE305041T1 AT01946702T AT01946702T ATE305041T1 AT E305041 T1 ATE305041 T1 AT E305041T1 AT 01946702 T AT01946702 T AT 01946702T AT 01946702 T AT01946702 T AT 01946702T AT E305041 T1 ATE305041 T1 AT E305041T1
- Authority
- AT
- Austria
- Prior art keywords
- compositions
- cgi
- directed
- present
- methods related
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 101000655476 Homo sapiens Probable mitochondrial glutathione transporter SLC25A39 Proteins 0.000 title 1
- 102100032871 Probable mitochondrial glutathione transporter SLC25A39 Human genes 0.000 title 1
- 102000015494 Mitochondrial Uncoupling Proteins Human genes 0.000 abstract 1
- 108010050258 Mitochondrial Uncoupling Proteins Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5035—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on sub-cellular localization
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5076—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving cell organelles, e.g. Golgi complex, endoplasmic reticulum
- G01N33/5079—Mitochondria
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Public Health (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21330700P | 2000-06-22 | 2000-06-22 | |
| PCT/US2001/020117 WO2001098355A2 (en) | 2000-06-22 | 2001-06-22 | Cgi-69 compositions and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE305041T1 true ATE305041T1 (de) | 2005-10-15 |
Family
ID=22794566
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01950401T ATE276363T1 (de) | 2000-06-22 | 2001-06-22 | Metabolismuskontrolle mittels zusamensetzungen des humanen 2-oxoglutarat-trägers |
| AT01946702T ATE305041T1 (de) | 2000-06-22 | 2001-06-22 | Kompositionen und verwendungen von cgi-69 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01950401T ATE276363T1 (de) | 2000-06-22 | 2001-06-22 | Metabolismuskontrolle mittels zusamensetzungen des humanen 2-oxoglutarat-trägers |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20020119137A1 (de) |
| EP (2) | EP1294881B1 (de) |
| AT (2) | ATE276363T1 (de) |
| AU (4) | AU2001271395B2 (de) |
| CA (2) | CA2414033A1 (de) |
| DE (2) | DE60113535T2 (de) |
| WO (2) | WO2001098512A2 (de) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001271395B2 (en) | 2000-06-22 | 2007-02-08 | Genentech, Inc. | Control of metabolism with compositions of the human 2-oxoglutarate carrier |
| WO2009035574A1 (en) * | 2007-09-10 | 2009-03-19 | Merck & Co., Inc. | Method for measuring mitochondrial membrane potential in vertebrate cells |
| US9950194B2 (en) | 2014-09-09 | 2018-04-24 | Mevion Medical Systems, Inc. | Patient positioning system |
| CN109629463B (zh) * | 2019-01-23 | 2023-12-08 | 河南中平交科研究设计院有限公司 | 一种桥梁端头加固结构及桥梁板端头裂缝处理工艺 |
| CN114837060B (zh) * | 2022-03-29 | 2024-01-12 | 江苏远方交通勘察设计研究院有限公司 | 一种桥梁建造工程用安全型临时栈道结构 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5206161A (en) | 1991-02-01 | 1993-04-27 | Genentech, Inc. | Human plasma carboxypeptidase B |
| SE9702457D0 (sv) * | 1997-06-26 | 1997-06-26 | Pharmacia & Upjohn Ab | Screening |
| US5932442A (en) | 1997-09-23 | 1999-08-03 | Incyte Pharmaceuticals, Inc. | Human regulatory molecules |
| AU4548299A (en) | 1998-06-08 | 1999-12-30 | Trustees Of Boston University | Novel methods for identifying modulators of mitochondrial anion carrier activity |
| WO2000004037A1 (en) | 1998-07-14 | 2000-01-27 | Amylin Pharmaceuticals, Inc. | Uncoupling protein 4 (ucp-4) and methods of use |
| EP1198474A4 (de) | 1999-04-09 | 2004-10-20 | Human Genome Sciences Inc | Entkoppelte proteine |
| AU2001271395B2 (en) | 2000-06-22 | 2007-02-08 | Genentech, Inc. | Control of metabolism with compositions of the human 2-oxoglutarate carrier |
-
2001
- 2001-06-22 AU AU2001271395A patent/AU2001271395B2/en not_active Ceased
- 2001-06-22 AU AU6871501A patent/AU6871501A/xx active Pending
- 2001-06-22 WO PCT/US2001/020020 patent/WO2001098512A2/en active IP Right Grant
- 2001-06-22 US US09/888,358 patent/US20020119137A1/en not_active Abandoned
- 2001-06-22 AT AT01950401T patent/ATE276363T1/de not_active IP Right Cessation
- 2001-06-22 EP EP01950401A patent/EP1294881B1/de not_active Expired - Lifetime
- 2001-06-22 DE DE60113535T patent/DE60113535T2/de not_active Expired - Lifetime
- 2001-06-22 WO PCT/US2001/020117 patent/WO2001098355A2/en active IP Right Grant
- 2001-06-22 EP EP01946702A patent/EP1294877B1/de not_active Expired - Lifetime
- 2001-06-22 CA CA002414033A patent/CA2414033A1/en not_active Abandoned
- 2001-06-22 DE DE60105609T patent/DE60105609T8/de active Active
- 2001-06-22 AT AT01946702T patent/ATE305041T1/de not_active IP Right Cessation
- 2001-06-22 AU AU7139501A patent/AU7139501A/xx active Pending
- 2001-06-22 US US09/888,264 patent/US7141421B2/en not_active Expired - Fee Related
- 2001-06-22 AU AU2001268715A patent/AU2001268715B2/en not_active Ceased
- 2001-06-22 CA CA002414065A patent/CA2414065A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| DE60113535D1 (de) | 2006-02-02 |
| WO2001098355A2 (en) | 2001-12-27 |
| CA2414065A1 (en) | 2001-12-27 |
| EP1294881A2 (de) | 2003-03-26 |
| CA2414033A1 (en) | 2001-12-27 |
| US20020103150A1 (en) | 2002-08-01 |
| WO2001098512A2 (en) | 2001-12-27 |
| US7141421B2 (en) | 2006-11-28 |
| DE60105609D1 (de) | 2004-10-21 |
| EP1294877A2 (de) | 2003-03-26 |
| AU7139501A (en) | 2002-01-02 |
| US20020119137A1 (en) | 2002-08-29 |
| AU6871501A (en) | 2002-01-02 |
| AU2001271395B2 (en) | 2007-02-08 |
| EP1294881B1 (de) | 2004-09-15 |
| WO2001098512A3 (en) | 2003-01-03 |
| DE60113535T2 (de) | 2006-06-22 |
| WO2001098355A3 (en) | 2002-10-03 |
| EP1294877B1 (de) | 2005-09-21 |
| DE60105609T8 (de) | 2006-02-16 |
| ATE276363T1 (de) | 2004-10-15 |
| AU2001268715B2 (en) | 2007-01-11 |
| DE60105609T2 (de) | 2005-09-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA200201214A1 (ru) | Замещенные тиоацетамиды | |
| TR200602095T2 (tr) | Hümanize Anti-LT-Beta-R antikorları | |
| CY1108610T1 (el) | Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες | |
| NO20030845D0 (no) | Utvalgte fusjonerte pyrrolokarbazoler | |
| HN2001000217A (es) | Nuevos tiadiazoles y oxadiazoles y su uso como inhibidores de fosfodiesterasa - 7 | |
| EA200300171A1 (ru) | Циклопентаноиндолы, композиции, содержащие данные соединения, и способы лечения | |
| DE60106954D1 (de) | Resorcin-derivate | |
| EA200400586A1 (ru) | Замещённые тиоацетамиды | |
| DK1368060T3 (da) | HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme | |
| EA200300929A1 (ru) | Новые лекарственные композиции на основе антихолинергических средств и ингибиторов pde-iv | |
| DE60013098D1 (de) | Zusammensetzung zur hautdesinfizierung | |
| DK1668001T3 (da) | Substituerede heteroarylbenzofuransyrer | |
| EA200201138A1 (ru) | Пептид, модулирующий рецептор тромбопоэтина | |
| NO20031860D0 (no) | Kahalaolid F | |
| MXPA03001643A (es) | Composiciones y metodos para el diagnostico y tratamiento de tumores. | |
| EP1578760A4 (de) | Zusammensetzungen und verfahren zur diagnose und behandlung von tumoren | |
| SE9904674D0 (sv) | Novel compounds | |
| DE60101559D1 (de) | Benutzung von comt-inhibitoren als analgetika | |
| BR0110577A (pt) | Decorina transgenicamente produzida | |
| ATE305041T1 (de) | Kompositionen und verwendungen von cgi-69 | |
| ATE557034T1 (de) | Identifikation von epitopen und erniedrigung der allergenität von nahrungsmittelproteinen | |
| TR200401875T2 (tr) | Endoparazit öldürücü bileşimler | |
| ATE455579T1 (de) | Sojaprodukte enthaltende zusammensetzungen | |
| DE60215795D1 (de) | Verwendung von betain in der haarpflege | |
| RS20060023A (en) | Use of soluble cd164 in inflammatory and/or autoimmune disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |